TABLE 2 Responses to decitabine in a phase I, low-dose study
From the following article:
Optimizing therapy with methylation inhibitors in myelodysplastic syndromes: dose, duration, and patient selection
Jean-Pierre Issa
BACK TO ARTICLESchedule (mg  days) | No. of patients | CR + PR No. (%) | Total dose(mg) |
|---|---|---|---|
CR, complete remission; PR, partial remission. This research was originally published in Blood. Issa JP et al (2004) Phase I study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in hematopoietic malignancies. Blood103: 1635–1640. © The American Society of Hematology. | |||
| 5 10 | 5 | 2 (40) | 50 |
| 10 10 | 6 | 1(17) | 100 |
| 15 10 | 17 | 11 (65) | 150 |
| 20 10 | 8 | 1 (13) | 200 |
| 15 15 | 7 | 1 (14) | 225 |
| 15 20 | 3 | 0 (0) | 300 |
| 75 10 | 17 | 1 (6) | 750 |
